Lipid‐based nutrient supplements do not affect efavirenz but lower plasma nevirapine concentrations in Ethiopian adult HIV patients
- 13 May 2015
- journal article
- research article
- Published by Wiley in HIV Medicine
- Vol. 16 (7) , 403-411
Abstract
Objectives: Lipid‐based nutrient supplements (LNSs) are increasingly used inHIVprogrammes in resource‐limited settings. However, the possible effects ofLNSson the plasma concentrations of antiretroviral drugs have not been assessed. Here, we aimed to assess the effects ofLNSson plasma efavirenz and nevirapine trough concentrations inEthiopian adultHIV‐infected patients.Methods: The effects ofLNSswere studied in adults initiating antiretroviral therapy (ART) in a randomized trial. Patients with body mass index (BMI) > 17 kg/m2(n = 282) received daily supplementation of anLNScontaining whey (LNS/w), anLNScontaining soy (LNS/s) or noLNS. Trough plasma concentrations of efavirenz and nevirapine were measured at 1 and 2 months. Genotyping for 516G>Tand 983T>Cpolymorphisms of thecytochromeP450(CYP)2B6locus was performed. Multilevel linear mixed‐effects models were used to assess the associations betweenLNSand plasma efavirenz and nevirapine concentrations.Results: In patients withBMI> 17 kg/m2, nevirapine concentrations were lower in theLNS/w andLNS/s groups by a median of −2.3 μg/mL [interquartile range (IQR) −3.9; −0.9 μg/mL;P = 0.002] and −2.1 μg/mL (IQR−3.9; −0.9 μg/mL;P = 0.01), respectively, compared with the group not receiving supplements. There were no differences between groups with respect to efavirenz plasma concentrations. TheCYP2B6516G>Tpolymorphism was associated with a 5 μg/mL higher plasma efavirenz concentration compared with the wild type (P < 0.0001), while it was not associated with plasma nevirapine concentrations.Conclusions: Intake of anLNSwas associated with lower plasma nevirapine trough concentrations, indicating possible drug−LNSinteractions. The clinical relevance of such reductions in nevirapine exposure is not clear. Plasma efavirenz concentration was not affected by theLNS.Keywords
Funding Information
- DANIDA-GRANT (09-026RH)
This publication has 29 references indexed in Scilit:
- Outcomes for Efavirenz versus Nevirapine-Containing Regimens for Treatment of HIV-1 Infection: A Systematic Review and Meta-AnalysisPLOS ONE, 2013
- Nutrition and pharmacology: general principles and implications for HIVThe American Journal of Clinical Nutrition, 2011
- Nevirapine Plasma Concentrations Are Associated with Virologic Response and Hepatotoxicity in Chinese Patients with HIV InfectionPLOS ONE, 2011
- Nutrition outcomes of HIV‐infected malnourished adults treated with ready‐to‐use therapeutic food in sub‐Saharan Africa: a longitudinal studyJournal of the International AIDS Society, 2011
- Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmesThe Lancet, 2010
- Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patientsAIDS Research and Therapy, 2010
- Use of lipid‐based nutrient supplements (LNS) to improve the nutrient adequacy of general food distribution rations for vulnerable sub‐groups in emergency settingsMaternal & Child Nutrition, 2009
- Co-administration of fluconazole increases nevirapine concentrations in HIV-infected UgandansJournal of Antimicrobial Chemotherapy, 2009
- Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adultsAIDS, 2008
- Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosisJournal of Antimicrobial Chemotherapy, 2007